SCHEMBL5353446

SCHEMBL5353446

CC(=O)Nc1cccc(CCCCCCC(=O)O)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.63
KMT2A Q03164 2/20 0.63
MAPT P10636 1/20 0.57
RXFP1 Q9HBX9 1/20 0.57
NPSR1 Q6W5P4 1/20 0.52
AOC3 Q16853 1/20 0.51
GFER P55789 1/20 0.50
RAB9A P51151 4/20 0.49
NPC1 O15118 2/20 0.49
POLB P06746 2/20 0.49
KDM4A O75164 1/20 0.49
KDM5A P29375 1/20 0.49
KDM4C Q9H3R0 1/20 0.49
PHF8 Q9UPP1 1/20 0.49
KDM2A Q9Y2K7 1/20 0.49
ITGB3 P05106 1/20 0.48
ITGA2B P08514 1/20 0.48
TBXAS1 P24557 2/20 0.48
NR4A1 P22736 1/20 0.48
ALDH1A1 P00352 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5106598 0.99 MEN1 (0.65) MEN1KMT2AMAPTRXFP1NPSR1
SCHEMBL15295153 0.94 MEN1 (0.67) MEN1KMT2AMAPTNPSR1AOC3
SCHEMBL22526066 0.88 AOC3 (0.53) MEN1KMT2AMAPTNPSR1AOC3
SCHEMBL10752853 0.88 MEN1 (0.61) MEN1KMT2AMAPTNPSR1AOC3
SCHEMBL25122909 0.86 RAB9A (0.52) MEN1KMT2AMAPTNPSR1AOC3
SCHEMBL22526185 0.86 AOC3 (0.49) MEN1KMT2ANPSR1AOC3RAB9A
SCHEMBL22600359 0.85 MAPT (0.60) MAPTRXFP1KDM4AKDM5AKDM4C
SCHEMBL26224474 0.85 AOC3 (0.48) MEN1KMT2ANPSR1AOC3RAB9A
SCHEMBL11503362 0.84 MAPT (0.57) MEN1KMT2AMAPTRXFP1GFER
SCHEMBL13483465 0.84 S1PR1 (0.56) MEN1KMT2AMAPTNPSR1AOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7253194-B2 Compounds and inhibitors of phospholipases THE UNIVERSITY OF QUEENSLAND (AU) 2007-08-07 US disclosed
EP-1309552-A4 COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES UNIV QUEENSLAND (AU) 2005-07-20 EP disclosed
US-20040033995-A1 Compounds and inhibitors of phospholipases QUEENSLAND, THE UNIVERSITY OF (AU) 2004-02-19 US disclosed
EP-1309552-A1 COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES THE UNIVERSITY OF QUEENSLAND (AU) 2003-05-14 EP disclosed
WO-2002008189-A1 COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES THE UNIVERSITY OF QUEENSLAND (AU) 2002-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040033995-A1 Compounds and inhibitors of phospholipases PLA2G4C, PLA2G4B, PLA2G4A MEN1 3515/4885KMT2A 4111/4885MAPT 3460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.